Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of NXP001 vs Emend in Healthy Volunteers
NCT03889366Phase 1Completed
- Sponsor
- Nuformix
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NXP001 in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Nuformix. Primary endpoint: Area Under the Curve (AUC(0 to Infinity)). Started Mar 2019; status: completed.
02
Drugs
NXP001
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03889366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889366.